|
Features
Announcements
About Us
|
|
Undiagnosed Diseases Gene Function Research (R21)
Applications due June 14, 2013
Expires June 15, 2013
Detection of Pathogen-Induced Cancer (R01)
Application due dates: July 10, 2013; December 11, 2013; July 10, 2014; December 11, 2014; July 10, 2015; December 11, 2015
Expires December 12, 2015
Imaging and Biomarkers for Early Cancer Detection (R01)
Application due dates: July 10, 2013; December 11, 2013; July 10, 2014; December 11, 2014; July 10, 2015; December 11, 2015
Expires December 12, 2015
Genomic Medicine Pilot
Demonstration Projects (U01)
Applications due July 17, 2013
Expires July 18, 2013 |
|
NOT-CA-13-009
Regarding Opportunities for Cancer-relevant Innovative Technologies with Transformative Potential
(RFI)
Response Date: June 30, 2013
|
|
NOT-OD-13-061
Reminder to Use the Research Performance Progress Report (RPPR)
Grantee institutions should use the Research Performance Progress Report for All SNAP and Fellowship Progress Reports for awards with start dates on or after July 1, 2013.
|
|
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
9609 Medical Center Drive
4 East, MSC 9763
|
|
 |
 |
Each year, the Epidemiology and Genomics Research Program invites extramural investigators to nominate research publications that were fully or partially funded by EGRP grants for our annual Research Highlights. From the more than 90 nominations we received in response to our latest call for publications, EGRP staff chose ten to feature, based on potential scientific and/or public health impact. The 2012 Research Highlights include publications relevant to
More details about the 2012 Research Highlights publications can be found on the EGRP website. We thank everyone who submitted publications for consideration.
|
Special Journal Series: Cancer Epidemiology in the 21st Century 
|
 In April 2013, the American Association for Cancer Research's Cancer Epidemiology, Biomarkers and Prevention (CEBP) published a new series of commentaries, "Cancer Epidemiology in the 21st Century." This editorial series was assembled in response to an NCI initiative and a guest editorial was written by EGRP's Associate Director, Dr. Muin J. Khoury.
The commentaries discuss opportunities and challenges for genomic epidemiology, translational research, emerging technologies, multilevel approaches, key research questions, and knowledge integration. They are intended to inspire scientists from many disciplines to elevate the quality and impact of epidemiological science in the coming years.
All articles in the "Cancer Epidemiology in the 21st Century" series are available on the CEBP website. If you have suggestions or questions about these commentaries--or about future directions in epidemiology--we invite you to comment on our Blog.
|
International Collaboration of Consortia Links New DNA Regions to Breast, Ovarian, and Prostate Cancers
| In March 2013, several scientific journals--Nature Genetics, PLoS Genetics, The American Journal of Human Genetics, Molecular Genetics, and Nature Communications--featured new research findings from the Collaborative Oncological Gene-environment Study (COGS).
The COGS international mega-collaboration includes many NCI-supported investigators from EGRP-supported research consortia and from the NCI-funded Genetic Associations and Mechanisms in Oncology (GAME-ON) network. It was designed to advance scientific understanding of genetic susceptibility to three hormone-related cancers: breast, ovarian, and prostate cancer. The initiative examined hundreds of thousands of locations in the genomes of more than 250,000 people with and without cancer. The results represent a milestone in epidemiology; researchers discovered many new regions linked with overall risk for breast, ovarian, and prostate cancer, as well as confirming previously known genetic markers.
These results demonstrate the value of continued large-scale, international, scientific collaborations and arrays designed for mega-analysis. A new custom genotyping array, the "OncoChip," is currently being designed by investigators from the United Kingdom and the United States to provide further genetic characterization of breast, ovarian, prostate, colorectal, and lung cancers.
In a Nature Genetics commentary, the authors summarize and provide insights into this collection of papers from COGS and GAME-ON investigators; the implications of the results and future directions for such efforts are also discussed.
The commentary and 13 other papers are available in the April Nature Genetics iCOGS Focus issue (published online March 27, 2013).
|
EGRP International Conference Focuses on Isocyanates and Health
|
Scientists, regulators, worker representatives, industry representatives, clinicians, and others met on April 3-5, 2013 at the Bolger Conference Center in Potomac, MD for a conference on "Isocyanates & Health: Past, Present, and Future."
Isocyanates are components of polyurethane products, which include common household items such as foam insulation, sealants, and mattresses. The purpose of this international, multidisciplinary conference was to identify and discuss the latest knowledge and important issues on the health effects of isocyanates, including current best evidence about exposure monitoring, environmental controls, and clinical management.
The conference sponsors included the NCI, the National Institute of Environmental Health Sciences (NIEHS), and several other government agencies and professional organizations. EGRP's Gary L. Ellison, Ph.D., M.P.H., was a member of the conference's Scientific Committee and chair of the Human Cancer Risk session. Although a conference summary is still being developed, a brief synopsis is available in the May 2013 issue of the NIEHS Environmental Factor newsletter.
Learn more about EGRP's interests in environmental epidemiology.
|
EGRP Hosts Meeting on Cancer Treatment-Related Cardiotoxicity
|
On March 20 and 21, 2013, EGRP co-hosted a joint National Cancer Institute (NCI) and National Heart, Lung and Blood (NHLBI) Workshop on "Cancer Treatment-Related Cardiotoxicity: Understanding the Current State of Knowledge and Developing Future Research."  The meeting brought together multiple disciplines within cardiology and oncology to identify research priorities aimed at improving the cardiac outcomes of cancer survivors. Meeting participants agreed that knowledge gaps must be addressed across disciplines, from basic science to risk prediction, screening, prevention, and treatment, and including chemotherapy, biologically targeted agents, and radiation-induced toxicity. Meeting outcomes will be used by NCI and NHLBI to better inform future funding opportunity announcements and initiatives.
More information--including the meeting agenda, video of both days of the meeting, and a compilation of relevant scientific publications--is available on the meeting website.
|
We've Moved
| |
Update your address books with our new contact information
On May 3, 2013, EGRP staff moved to the brand new NCI Shady Grove campus. The new NCI building is more energy-efficient (LEED certified) than our former offices and has more conference rooms and meeting spaces, which will allow us to host a greater number of formal and informal meetings with the extramural community.
If you're communicating with our staff in the coming weeks, be sure to note the new phone number in their e-mail signature (or search for their new number in our updated Staff List).
The new mailing address and office phone number can also be found on our Contact Us page.
|
|
